A 24 week randomized, double-blind, placebo-controlled, parallel group, efficacy and safety trial of once daily linagliptin, 5 milligrams orally, as add on to basal insulin in elderly Type 2 Diabetes Mellitus patients with insufficient glycaemic control
Phase of Trial: Phase IV
Latest Information Update: 10 Dec 2017
At a glance
- Drugs Linagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 10 Jun 2017 Biomarkers information updated
- 24 May 2017 Status changed from active, no longer recruiting to completed.
- 06 Apr 2017 This trial has been completed in UK (End date:2016-09-27) as per European Clinical Trials Database record.